重型血友病A患者接受valoctocogene roxaparvovec基因治疗后的健康相关生活质量:3期试验GENEr8-1结果
在3期试验GENEr8-1中,132例无抑制物的重型血友病A成年男性接受6×10^13 vg/kg valoctocogene roxaparvovec输注后,Haemo-QOL-A总分在12周时平均变化达到锚定临床重要差异(CID 5.5),第104周平均(SD)升高7.0(12.6)。出血后果、治疗担忧、忧虑和角色功能领域评分改善超过CID(6)。EQ-5D-5L效用指数在52周改善超过CID,但104周未超过。结论认为该基因治疗提供了有临床意义的生活质量改善。
要点
- 132例HIV阴性重型血友病A男性接受6×10^13 vg/kg valoctocogene roxaparvovec后,Haemo-QOL-A总分第12周改善达到CID(5.5)。
- 第104周Haemo-QOL-A总分平均(SD)较基线升高7.0(12.6),出血后果、治疗担忧、忧虑和角色功能领域改善超过CID(6)。
- 有Problem关节者基线Haemo-QOL-A总分及领域评分低于无Problem关节者,但104周内改善,≥3个Problem关节的11例除外。
核心结论
- Valoctocogene roxaparvovec为重型血友病A男性提供了有临床意义的生活质量改善。
研究设计与样本
- 3期试验GENEr8-1的事后分析,纳入132例无抑制物的重型血友病A成年男性,接受6×10^13 vg/kg valoctocogene roxaparvovec输注。
- 参与者报告结局包括Haemo-QOL-A、EQ-5D-5L、HAL和WPAI+CIQ:HS,在基线和输注后至104周完成问卷。
主要发现
- 132例HIV阴性参与者Haemo-QOL-A总分第12周平均变化达到锚定CID(5.5),第104周平均(SD)升高7.0(12.6)。
- 第104周出血后果、治疗担忧、忧虑和角色功能领域评分改善超过CID(6)。
- EQ-5D-5L效用指数第52周改善超过CID,但第104周未超过CID。
- EQ-5D-5L视觉模拟量表和HAL评分从基线至第104周升高;第104周活动和工作损害较基线减少。
- 有Problem关节者基线Haemo-QOL-A总分及领域评分低于无Problem关节者,但104周内改善,≥3个Problem关节的11例除外;基线预防治疗期0次出血者Haemo-QOL-A评分改善超过CID,包括出血后果领域。
关键数值与推荐
- Haemo-QOL-A总分锚定CID为5.5,领域CID为6。
- 132例HIV阴性参与者第104周Haemo-QOL-A总分平均(SD)较基线升高7.0(12.6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe hemophilia A (HA) negatively impacts health-related quality of life (HRQOL). OBJECTIVES: We aimed to analyze HRQOL in adult men with severe HA without inhibitors after valoctocogene roxaparvovec gene transfer in the phase 3 trial GENEr8-1. METHODS: Participant-reported outcomes were the hemophilia-specific quality of life questionnaire for adults (Haemo-QOL-A), the EQ-5D-5L instrument, the Hemophilia Activities List (HAL), and the Work Productivity and Activity Impairment Questionnaire: Hemophilia Specific (WPAI+CIQ:HS). Participants completed the questionnaires at baseline and through 104 weeks postinfusion with 6 × 1013 vg/kg of valoctocogene roxaparvovec. Scores were analyzed per participant characteristics and outcomes. RESULTS: For 132 HIV-negative participants, mean change from baseline in Haemo-QOL-A Total Score met the anchor-based clinically important difference (CID: 5.5) by week 12; the mean (SD) increase was 7.0 (12.6) at week 104. At week 104, improvement in Consequences of Bleeding, Treatment Concern, Worry, and Role Functioning domain scores exceeded the CID (6). EQ-5D-5L Utility Index scores improved above the CID at week 52, but not at week 104. EQ-5D-5L visual analog scale and HAL scores increased from baseline to week 104. Participants reported less activity and work impairment at week 104 than baseline. Participants with problem joints had lower mean baseline Haemo-QOL-A Total and domain scores than those without them, but improved over 104 weeks, except for 11 participants with ≥3 problem joints. Participants with 0 bleeds during the baseline prophylaxis period reported Haemo-QOL-A score improvements above the CID, including in the Consequences of Bleeding domain. CONCLUSION: Valoctocogene roxaparvovec provided clinically meaningful HRQOL improvement for men with severe HA.
引用
- O'Mahony B, Dunn AL, Leavitt AD, et al. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023. PMID: 37678546. doi:10.1016/j.jtha.2023.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。